Kiniksa Pharmaceuticals International, plc

Good day, and thank you for standing by. Welcome to the Connexa Pharmaceuticals third quarter 2023 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that session, you will need to press star 11 on your phone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded, and I would now like to hand the conference over to your speaker today, Ms. Rachel Frank. Please go ahead.

Thank you, Operator. Good morning, everyone, and thank you for joining Connective Call to discuss our third quarter 2023 financial results in recent portfolio execution. Press release highlighting these results can be found on our website under the Investor section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Ross Moat, our chief commercial officer, will provide an update on our commercial execution. John Paolini, our chief medical officer, will provide a KPL 404 program review. Then Mark Ragosa, our chief financial officer, will review our third quarter 2023 financial results. And finally, Sondra will return for closing remarks and to kick off the Q&A session. Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements. A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC filing. These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements, except as required by law. With that, I will turn it over to Sanj.

Thanks Rachel and good morning everyone. I'm happy to review our third quarter 2023 financial results today. We've continued to advance all aspects of our business, including strong revenue growth with Arclist and clinical trial execution with KPL 404. On the commercial side, Q3 represented another quarter of growth for Arclist, with a net product revenue of $64.8 million. We continue to execute commercially, and we have seen strong prescriber adoption and patient enrollments in the third quarter. We also remain encouraged by the high patient satisfaction, payer approval rates, and the duration of therapy. And we're currently tracking towards the high end of our previously issued guidance of $220 to $230 million for 2023. We're also executing across our clinical development portfolio. And we have now completed enrollment of the third cohort of the phase two trial of KPL-404, which is our CD40 antagonist program. and is focused in rheumatoid arthritis. And we now expect data from cohorts one to three in the first quarter of 2024. This trial is designed to evaluate the efficacy, dose response, PK, and safety of chronic sub-Q dosing over a duration of 12 weeks. Dr. Jan Paolini will cover more details on this program in a moment. Additionally, we continue to pursue collaborative study agreements with Mabrilumab to evaluate its potential in rare cardiovascular diseases. This is a molecule that has the potential to impact a number of diseases. So with that, I'll turn it over to Ross to review our commercial execution of Arculus. Ross.